ClinVar Miner

Submissions for variant NM_000179.3(MSH6):c.1239G>T (p.Trp413Cys)

dbSNP: rs1114167736
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV001010501 SCV001170709 likely pathogenic Hereditary cancer-predisposing syndrome 2024-08-20 criteria provided, single submitter clinical testing The p.W413C variant (also known as c.1239G>T), located in coding exon 4 of the MSH6 gene, results from a G to T substitution at nucleotide position 1239. The tryptophan at codon 413 is replaced by cysteine, an amino acid with highly dissimilar properties. An alteration resulting in the same amino acid change, c.1239G>C, has been classified as likely pathogenic in multiple individuals whose Lynch syndrome-associated tumor demonstrated high microsatellite instability and/or loss of MSH6 expression by immunohistochemistry (Ambry internal data). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on internal structural analysis, p.W413C is considered deleterious (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the majority of available evidence to date, this variant is likely to be pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.